Robert S Wallis

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. doi request reprint Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
    Robert S Wallis
    PPD Inc, Washington, DC 20005, USA
    Arthritis Rheum 58:947-52. 2008
  2. ncbi request reprint Reconsidering adjuvant immunotherapy for tuberculosis
    Robert S Wallis
    PPD, Washington, DC, USA
    Clin Infect Dis 41:201-8. 2005
  3. ncbi request reprint Reactivation of latent granulomatous infections by infliximab
    Robert S Wallis
    University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA
    Clin Infect Dis 41:S194-8. 2005
  4. ncbi request reprint Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab
    Robert S Wallis
    UMDNJ New Jersey Medical School, Newark, NJ, USA
    Semin Arthritis Rheum 34:34-8. 2005
  5. ncbi request reprint Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma
    Robert S Wallis
    PPD, Washington, DC, USA
    J Investig Dermatol Symp Proc 12:16-21. 2007
  6. doi request reprint Acquired rifamycin resistance: pharmacology and biology
    Robert S Wallis
    UMDNJ NJ Medical School, 1213 N Street NW, Suite A, Washington, DC 20005 USA
    Expert Rev Anti Infect Ther 6:223-30. 2008
  7. ncbi request reprint Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity
    Oluwabunmi Y Saliu
    Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA
    J Infect Dis 194:486-92. 2006
  8. pmc Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity
    Ernestas Janulionis
    UMDNJ New Jersey Medical School, Newark, New Jersey, USA
    Infect Immun 73:2595-601. 2005
  9. ncbi request reprint Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
    Oluwabunmi Y Saliu
    UMDNJ New Jersey Medical School, 185 S Orange Avenue, MSB 185, Newark, NJ, USA
    J Antimicrob Chemother 60:994-8. 2007
  10. doi request reprint Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
    Robert S Wallis
    PPD Inc, Washington, DC, USA
    Lancet Infect Dis 8:601-11. 2008

Collaborators

Detail Information

Publications25

  1. doi request reprint Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
    Robert S Wallis
    PPD Inc, Washington, DC 20005, USA
    Arthritis Rheum 58:947-52. 2008
    ..These 2 pathogenic mechanisms cannot otherwise be readily distinguished...
  2. ncbi request reprint Reconsidering adjuvant immunotherapy for tuberculosis
    Robert S Wallis
    PPD, Washington, DC, USA
    Clin Infect Dis 41:201-8. 2005
    ..Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas...
  3. ncbi request reprint Reactivation of latent granulomatous infections by infliximab
    Robert S Wallis
    University of Medicine and Dentistry New Jersey, New Jersey Medical School, Newark, New Jersey, USA
    Clin Infect Dis 41:S194-8. 2005
    ..The ability of infliximab to disrupt established granulomas may be distinct from its ability to neutralize soluble TNF. Further research to elucidate the mechanism of the antigranuloma activity of infliximab is warranted...
  4. ncbi request reprint Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab
    Robert S Wallis
    UMDNJ New Jersey Medical School, Newark, NJ, USA
    Semin Arthritis Rheum 34:34-8. 2005
    ..TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed...
  5. ncbi request reprint Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma
    Robert S Wallis
    PPD, Washington, DC, USA
    J Investig Dermatol Symp Proc 12:16-21. 2007
    ..IL-10 production was equally suppressed by all three drugs, excluding excess IL-10 as a regulatory mechanism. The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFNgamma...
  6. doi request reprint Acquired rifamycin resistance: pharmacology and biology
    Robert S Wallis
    UMDNJ NJ Medical School, 1213 N Street NW, Suite A, Washington, DC 20005 USA
    Expert Rev Anti Infect Ther 6:223-30. 2008
    ..Limiting TB therapy to weekdays may promote the emergence of acquired drug resistance in patients with advanced AIDS and TB. A large, simple trial to examine this question is both warranted and feasible...
  7. ncbi request reprint Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity
    Oluwabunmi Y Saliu
    Department of Medicine, University of Medicine and Dentistry, New Jersey Medical School, Newark, USA
    J Infect Dis 194:486-92. 2006
    ..The risk of reactivation of latent Mycobacterium tuberculosis infection is greater with the TNF monoclonal antibody infliximab than with the soluble TNF receptor etanercept. The basis of this difference is not known...
  8. pmc Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity
    Ernestas Janulionis
    UMDNJ New Jersey Medical School, Newark, New Jersey, USA
    Infect Immun 73:2595-601. 2005
    ..Our findings indicate substantial variability in the capacity of clinical tuberculosis isolates to replicate in host cells in the face of innate host immunity...
  9. ncbi request reprint Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
    Oluwabunmi Y Saliu
    UMDNJ New Jersey Medical School, 185 S Orange Avenue, MSB 185, Newark, NJ, USA
    J Antimicrob Chemother 60:994-8. 2007
    ..The present study was conducted to determine the activity of OPC-67,683 in the in vitro tolerance model using drug-tolerant clinical Mycobacterium tuberculosis strains...
  10. doi request reprint Tumour necrosis factor antagonists: structure, function, and tuberculosis risks
    Robert S Wallis
    PPD Inc, Washington, DC, USA
    Lancet Infect Dis 8:601-11. 2008
    ..Clinical strategies for prevention and management of tuberculosis in patients treated with TNF blockers may be improved based on our evolving understanding of these differences...
  11. pmc Lack of activity of orally administered clofazimine against intracellular Mycobacterium tuberculosis in whole-blood culture
    Ernestas Janulionis
    University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103, USA
    Antimicrob Agents Chemother 48:3133-5. 2004
    ..Clofazimine was inactive whether it was tested alone or combined with other drugs that are used to treat multidrug-resistant tuberculosis, despite a total dose of 2 g. Kanamycin was the most active drug tested...
  12. ncbi request reprint Whole blood bactericidal activity during treatment of pulmonary tuberculosis
    Robert S Wallis
    Department of Medicine, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, NJ 07103, USA
    J Infect Dis 187:270-8. 2003
    ..018), both of which are indicative of prognosis. These findings indicate that measurement of WBA may have a role in assessing the sterilizing activity of new anti-TB drugs...
  13. ncbi request reprint A study of the immunology, virology, and safety of prednisone in HIV-1-infected subjects with CD4 cell counts of 200 to 700 mm(-3)
    Robert S Wallis
    The University Medicine and Dentistry of New Jersey New Jersey Medical School, Newark, USA
    J Acquir Immune Defic Syndr 32:281-6. 2003
    ..The potential role of corticosteroids as tools to examine this question will be limited by concerns regarding their toxicity; however, further studies of other agents to limit cellular activation in AIDS are warranted...
  14. ncbi request reprint Persistence, not resistance, is the cause of loss of isoniazid effect
    Robert S Wallis
    J Infect Dis 195:1870-1; author reply 1872-3. 2007
  15. ncbi request reprint Structural-functional relationships of TNF-alpha antagonists: next steps
    Frank J Dann
    Amgen Inc, Thousand Oaks, California 91320 1799, USA
    J Investig Dermatol Symp Proc 12:46-7. 2007
    ..The data presented in this supplement highlight the need for further research into these key areas, and illustrate our current understanding of the mode of action of TNF blockers as only the tip of the iceberg...
  16. ncbi request reprint TB chemotherapy: antagonism between immunity and sterilization
    Robert S Wallis
    Am J Respir Crit Care Med 169:771-2. 2004
  17. ncbi request reprint Can studies of the early bactericidal activity of rifapentine tell us how to prevent acquired rifamycin-resistant relapse?
    Robert S Wallis
    Am J Respir Crit Care Med 172:4-5. 2005
  18. ncbi request reprint Anti-tuberculosis treatment and infliximab
    Robert S Wallis
    Respir Med 99:1620-2. 2005
  19. ncbi request reprint Granulomatous infections due to tumor necrosis factor blockade: correction
    Robert S Wallis
    Clin Infect Dis 39:1254-5. 2004
  20. ncbi request reprint A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
    Robert S Wallis
    Department of Medicine, Case Western Reserve University, Cleveland, OH, USA
    AIDS 18:257-64. 2004
    ..This phase 1 study examined the safety, microbiology, immunology, and virology of TNF blockade using etanercept (soluble TNF receptor, Enbrel) during the initial treatment of HIV-associated tuberculosis...
  21. ncbi request reprint Surrogate markers to assess new therapies for drug-resistant tuberculosis
    Robert S Wallis
    Expert Rev Anti Infect Ther 5:163-8. 2007
  22. ncbi request reprint Here today--gone tomorrow: the case for transient acute tuberculosis infection
    Edward A Nardell
    Am J Respir Crit Care Med 174:734-5. 2006
  23. ncbi request reprint Clinical, microbiological, and immunological characteristics in HIV-infected subjects at risk for disseminated Mycobacterium avium complex disease: an AACTG study
    Rob Roy MacGregor
    Infectious Diseases Division, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    AIDS Res Hum Retroviruses 21:689-95. 2005
    ..MAC-specific T cell responses apparently develop and persist during DMAC, but are dysfunctional or too infrequent to prevent persistence...
  24. ncbi request reprint Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda
    Harriet Mayanja-Kizza
    Department of Medicine, Makerere University Medical School, Kampala, Uganda
    J Infect Dis 191:856-65. 2005
    ..Conclusion. The benefits of prednisolone therapy on immune activation and CD4(+) T cell counts do not outweigh the risks of adverse events in HIV-infected patients with TB and preserved immune function...
  25. pmc Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis
    Seon Hee Cheon
    Case Western Reserve University, Cleveland, Ohio, USA
    Clin Diagn Lab Immunol 9:901-7. 2002
    ..These experiments indicate that whole blood culture may be used to measure immunity to M. tuberculosis and that further studies of repeated BCG vaccination are warranted...